Literature DB >> 6821836

Inhibition by retinoid and ovariectomy of additional primary malignancies in rats following surgical removal of the first mammary cancer.

D L McCormick, Z L Sowell, C A Thompson, R C Moon.   

Abstract

Retinoids are highly effective inhibitors of mammary carcinogenesis in the rat. This study was designed to determine the influence of retinyl acetate and bilateral ovariectomy on the rate of new tumor appearance when treatment is started at the time of removal of an animal's first mammary tumor. Fifty-day-old virgin female Sprague-Dawley rats received a single intravenous injection of 35 mg N-methyl-N-nitrosourea per kg body weight. When an animal's first mammary tumor reached a diameter of 0.5 cm it was excised and the animal was entered into a treatment group: (1) intact, placebo diet; (2) intact, 328 mg retinyl acetate/kg diet; (3) ovariectomy, placebo diet; (4) ovariectomy, 328 mg retinyl acetate/kg diet. New tumor incidence was reduced from 94% in Group 1 to 15% in Group 4. Groups 2 and 3 had an intermediate tumor response. These data indicate that retinyl acetate and ovariectomy are active in cancer prevention when treatment is began after removal of a palpable tumor, a time at which preneoplastic lesions are present in the mammary glands.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6821836     DOI: 10.1002/1097-0142(19830215)51:4<594::aid-cncr2820510407>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  Ruta D Rao; Melody A Cobleigh; Robert Gray; Mark L Graham; Larry Norton; Silvana Martino; George Thomas Budd; James N Ingle; William C Wood
Journal:  Med Oncol       Date:  2010-09-28       Impact factor: 3.064

2.  Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.

Authors:  F Boccardo; L Canobbio; M Resasco; A U Decensi; G Pastorino; F Brema
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.